Literature DB >> 31859247

CDK4/6 inhibitors in breast cancer: one more step towards reduced mortality.

Giuseppe Curigliano1, Sibylle Loibl2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31859247     DOI： 10.1016/S1470-2045(19)30808-3

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  2 in total

Review 1.  Therapeutic potential of CDK4/6 inhibitors in renal cell carcinoma.

Authors:  Rebecca A Sager; Sarah J Backe; Elham Ahanin; Garrett Smith; Imad Nsouli; Mark R Woodford; Gennady Bratslavsky; Dimitra Bourboulia; Mehdi Mollapour
Journal:  Nat Rev Urol       Date:  2022-03-09       Impact factor: 16.430

2.  PARP and CDK4/6 Inhibitor Combination Therapy Induces Apoptosis and Suppresses Neuroendocrine Differentiation in Prostate Cancer.

Authors:  Cheng Wu; Shan Peng; Patrick G Pilié; Chuandong Geng; Sanghee Park; Ganiraju C Manyam; Yungang Lu; Guang Yang; Zhe Tang; Shakuntala Kondraganti; Daoqi Wang; Courtney W Hudgens; Debora A Ledesma; Mario L Marques-Piubelli; Carlos A Torres-Cabala; Jonathan L Curry; Patricia Troncoso; Paul G Corn; Bradley M Broom; Timothy C Thompson
Journal:  Mol Cancer Ther       Date:  2021-06-22       Impact factor: 6.261
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.